GALT
Galectin·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Stock Price Surged Significantly
MACD Golden Cross
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GALT
Galectin Therapeutics Inc.
The leading developer of therapeutics that target galectin proteins
Biological Technology
--
03/23/2012
NASDAQ Stock Exchange
15
12-31
Common stock
4960 Peachtree Industrial Blvd.
, Suite 240
, Norcross
, GA 30071
--
Galectin Therapeutics Inc., established in July 2000 as Pro Pharma, is a development-stage company engaged in drug development to create new therapies for cancer and fibrotic diseases. Glaxti's drug candidate is based on an approach targeting the galactoagglutinin protein, a key mediator of biological and pathological functions. Glaxti uses naturally occurring, readily available plant materials as raw materials to create proprietary complex carbohydrates with specific molecular weights and pharmaceutical properties during the production process.
Company Financials
EPS
GALT has released its 2025 Q3 earnings. EPS was reported at -0.13, versus the expected -0.11, missing expectations. The chart below visualizes how GALT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
